Patient Recruitment in Clinical Trials: Why the Industry's Longstanding Approach Is No Longer Fit for Purpose

Patient recruitment has always been one of clinical development's most persistent and costly challenges, but a convergence of regulatory change, diversity expectations, and community trust deficits is forcing sponsors to fundamentally rethink how they identify, engage, and retain trial participants. The study-by-study, outreach-driven model that has defined recruitment for decades is giving way to something more programmatic, relational, and behaviorally informed.

Here are 10 questions addressing the key challenges and opportunities shaping patient recruitment in clinical trials today.

1. How is the FDA's shift to a single pivotal trial standard changing the stakes for patient recruitment?

The February 2026 announcement has concentrated sponsor attention on recruitment in ways that were not previously typical. As Gaynor Anders, chief delivery officer at Trialbee, described it in a recent interview with Applied Clinical Trials: "Recruitment will be a lot less forgiving than it has ever been before. You get one shot at it. That's the phrase I keep hearing from sponsors."

The elimination of parallel studies as a fallback means that feasibility must start earlier and be more precise, diversity requirements are under greater scrutiny, and patient quality matters as much as volume. Anders also noted that recruitment decisions are now being escalated to board level, reflecting how significantly the risk profile has shifted.

2. Why has the study-by-study approach to building patient pipelines persisted for so long, and what is driving the shift away from it?

Clinical research has historically been protocol-centric, with study teams focused on filling individual studies rather than building relationships with patient communities across therapeutic areas. The model has persisted partly because of organizational structure and partly because the cost of its inefficiency was easier to absorb when multiple studies provided redundancy.

What is changing, as Anders described, is a move toward patient centricity within a relationship-building context: "Sponsors building relationships with groups of patients, enabling them to sign up to communities where they can receive information about the work a sponsor is doing, and thinking about studies programmatically."

3. What does a programmatic approach to recruitment actually require from sponsors operationally?

The operational requirements are as much organizational as technological. As Anders was direct about, the first requirement is that study teams stop working in silos: "Different study teams know what's happening on their own study but don't necessarily know what their peers are working on. That has to change."

Budget structures also need to evolve, with cross-study funding mechanisms that allow efficiencies to be shared across therapeutic areas and compound leads. On the technology side, patient recruitment platforms need to integrate with CTMS systems and support end-to-end analytics tracking so that data flows from patient identification through to site enrollment without creating additional burden for study teams.

4. What are the biggest barriers to adopting portfolio-level recruitment, and how are sponsors addressing them?

Mindset is among the most persistent barriers. As Anders explained, making the shift requires sponsors to think beyond individual studies and consider what the approach means for patients across an entire therapeutic area, including studies that may not yet be finalized or listed on ClinicalTrials.gov. Siloed budgets and teams with limited cross-functional visibility compound the structural challenge.

The solution, in Anders' experience, involves protocol mapping to identify how studies can be brought together into a program, followed by the organizational work of encouraging teams to collaborate and securing the budget flexibility to support it.

5. What are the structural and relational barriers that most commonly limit participation from underrepresented communities?

Del Smith, PhD, CEO and co-founder of Acclinate, draws a clear distinction between the two categories. Structural barriers include site location, visit timing, travel distance, and compensation. Relational barriers are more deeply rooted.

In a Q&A with ACT, he said: "Are you engaging with the right people? Are you doing that in a sustained way? Have you built a level of trust with the individual before just coming in and asking them to be part of a study?"

Smith added that cultural relevance and understanding lived experiences are relational dimensions that sponsors frequently overlook, often to the detriment of their recruitment outcomes in communities where trust deficits run deep.

6. How does authentic community engagement differ from traditional recruitment outreach, and why does that distinction matter?

Traditional outreach is transactional: it arrives just before a study opens and disappears once enrollment is complete. Authentic engagement is sustained, relationship-based, and grounded in a genuine understanding of lived experience.

As Smith put it: "Lived experience is truly understanding, recognizing, and then making modifications to the way you engage with the community based on meeting them where they are."

The practical difference matters for feasibility because sustained engagement builds what Smith describes as a well of people who are willing and ready to participate, making the entire recruitment process more efficient when a study opens. Logistical mitigations alone, such as covering travel or simplifying consent, are incomplete without this relational foundation.

7. Why does clinical eligibility consistently fail to predict whether a patient will actually enroll?

Even patients who meet every medical requirement routinely make enrollment decisions based on three deeply human factors: trust in the investigators and institutions behind the research, hope for personal or societal benefit, and fear of exploitation or harm.

Standard education-based outreach supports the rational case for participating but does little to address the affective trust that comes from emotional connection and relational credibility, which is what ultimately moves hesitant but eligible patients toward enrollment.

8. What is the access-visibility gap and why does it matter for recruitment strategy?

The data infrastructure underlying modern recruitment, including EHRs, claims databases, and registries, reflects healthcare access and utilization, not true population health. Individuals facing systemic socioeconomic barriers or deep institutional mistrust generate little to no clinical records, making them statistically invisible to traditional recruitment algorithms. This creates a structural blind spot: the very communities whose trust most needs to be earned are frequently invisible to the systems sponsors use to find participants.

No algorithmic correction applied downstream can compensate for a population that was never captured upstream, which is why community-based engagement that predates recruitment is operationally necessary, not optional.

9. How can behavioral readiness be made operational within recruitment planning?

Platforms built around sustained community relationships capture behavioral and attitudinal signals through engagement with churches, HBCUs, advocacy groups, and trusted local organizations, identifying where communities are already primed to consider research participation. These signals allow sponsors to distinguish the participation-ready from the participation-resistant and to match not just the message but the messenger and the channel to a community's actual trust profile.

Three immediate structural changes support this transition: embedding behavioral readiness screeners into feasibility alongside clinical eligibility, investing in sustained non-transactional community presence, and training site teams in the emotional dimensions of patient decision-making.

10. What does success look like for CROs and sponsors in a programmatic, relationship-based recruitment model?

Success in this model is fundamentally about partnership and shared data visibility across the triangle of sponsor, CRO, and patient recruitment partner. As Anders framed it: "When we can work hand in hand with the CRO from the patient recruitment side of things, we can help the CRO succeed, which in turn helps the sponsor succeed."

Analytics visibility into how studies are performing within a program, and how patient pipelines carry forward into future studies, is the practical measure of whether the infrastructure is working.

For Smith, the long-term value extends beyond enrollment targets: "Instead of starting this whole process over again when your next study starts, you have an on-ramp to a much faster ability to engage and recruit. What you'll find is that sustained engagement over time has an exponential impact on your future studies."